Natera has reported two new partnerships to launch its Panorama non-invasive prenatal screening test (NIPT) outside of the US. The Joaquim Chaves Group will manage the distribution of Panorama in Portugal, and Bangkok Cytogenetics Center will manage its distribution in Thailand.
Panorama has been validated globally in multiple clinical trials and has demonstrated high sensitivity and specificity for all major aneuploidies beyond Down's syndrome, including trisomy 13 (and 18, as well as sex chromosome abnormalities. Panorama is also claimed to be the only commercially available NIPT capable of screening for triploidy.
Panorama analyses cell-free DNA in maternal blood using a simple blood draw and can be performed as early as nine weeks without any risk to the foetus. Panorama uses an advanced, bioinformatics-based algorithm called NATUS [Next-generation Aneuploidy Testing Using SNPs] that analyses approximately 19,500 single nucleotide polymorphisms (SNPs) in a single reaction. These SNPs are combined with genetic information from the parents and data from the Human Genome Project to generate hypotheses of the potential foetal genotypes. These billions of hypotheses are then compared to the actual cell-free DNA measurements to determine the presence or absence of a chromosomal abnormality in the foetus.